Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in …
Industry Peers
Medical Devices| Headline | Source | Time |
|---|---|---|
Older | ||
 Co-Dx (CODX) Q2 2026 Earnings Call Transcript Net loss narrowed to $6.3 million as operating costs fell and FDA submissions advanced. | ||
 Co-Diagnostics, Inc. Q2 2026 Earnings Call Summary Moby summary of Co-Diagnostics, Inc.'s Q2 2026 earnings call | ||
Co-Diagnostics Inc (CODX) (Q2 2026) Earnings Call Highlights: FDA Submission Milestone and ... Co-Diagnostics Inc (CODX) narrows Q2 2026 net loss to $6.3 million while advancing key regulatory submissions for its flu/RSV panel and tuberculosis test. | ||
 OraSure Technologies Q2 Earnings Call Highlights OraSure Technologies (NASDAQ:OSUR) reported second-quarter revenue of $30.6 million, exceeding its guidance range and rising 9.7% sequentially, as stronger public-health diagnostics demand and growth in sample-management products supported results. President and Chief Executive Officer Carrie Eglin | ||
 EXCLUSIVE: Co-Diagnostics Announces Successful Proof of Concept for Extraction-Free Ebola Test Co-Diagnostics Inc., a molecular diagnostics firm, announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., shipped evaluation kits of its SARAGENE Bundibugyo Virus Test to an independent testing facility. The distribution was initiated at the behest of the India... | ||
 EXCLUSIVE: Co-Diagnostics Announces Successful Proof of Concept for Extraction-Free Ebola Test Co-Diagnostics Inc. (NASDAQ:CODX), a molecular diagnostics firm, announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., shipped evaluation kits of its SARAGENE Bundibugyo Virus Test to an independent testing facility. The distribution was initiated at the behest of the India Center for Cellular and Molecular Platforms (C-CAMP), an initiative backed by the India Department of Biotechnology. Expanding Point-Of-Care Diagnostics For Virus Testing Alongside deploying these test kits, | ||
 EXCLUSIVE: Co-Diagnostics Marks New Milestone as India TB Test Clinical Studies Begin Co-Diagnostics Inc. (NASDAQ:CODX) on Wednesday said CoSara Diagnostics Pvt. Ltd, its joint venture in India, is initiating clinical studies for the tuberculosis test on the CoSara PCR Pro instrument. The molecular diagnostics company said the initiation of these clinical studies marks another critical milestone for the Co-Dx PCR platform, following the company’s previously announced shipment of PCR Pro instruments, mycobacterium tuberculosis (TB or MTB) test kits and proprietary sample preparati | ||
MMT Newswires | ||